Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04865133 · ClinicalTrials.gov registry record
Efficacy and Safety of COVID-19 Vaccine in Cancer Patients
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 89
- Enrollment target
NCT04865133: Completed study, sponsored by Mayo Clinic.
NCT04865133 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04865133 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
Study Summary
This study gathers information about how a cancer patient responds to COVID-19 vaccine during cancer treatment compared to healthy individuals. The information gained may help determine how effective currently available COVID-19 vaccines are in cancer patients receiving chemotherapy and learn more regarding how long an immune response will last compared to healthy individuals.
Primary Outcome
Wilcoxon rank sum test will be used to compare between baseline and other 3 time points (before the second vaccination, 3 months, and 12 months after the second vaccination).
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2022-09-08 |
What the finished NCT04865133 record still lists
NCT04865133 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04865133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04865133 about?
NCT04865133 is a clinical study titled "Efficacy and Safety of COVID-19 Vaccine in Cancer Patients". This study gathers information about how a cancer patient responds to COVID-19 vaccine during cancer treatment compared to healthy individuals. The information gained may help determine how effective currently available COVID-19 vaccines are in cancer patients receiving chemotherapy and learn more r...
What is the current status of trial NCT04865133?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2021-03-31. Estimated completion is 2022-09-08.
What interventions are being tested in trial NCT04865133?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT04865133?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI